Vifor Pharma AG
VIFN.SW
Swiss Exchange166.15
CHF
+0.80
- -
Vifor Pharma AG
VIFN.SW
(Swiss Exchange)
Recent
price
166.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Vifor Pharma AG, a global specialty pharmaceuticals company, develops, manufactures, and markets innovative therapies focused on iron deficiency, nephrology, dialysis, and cardio-renal conditions; its core products include Ferinject/Injectafer (iron deficiency treatments approved in 87 countries), Venofer, Veltassa (hyperkalemia management), Velphoro, Rayaldee, Mircera, Retacrit, vadadustat, difelikefalin, Korsuva, and FILSPARI (sparsentan for IgA Nephropathy). The company operates in over 100 countries across North and South America, Europe, the Middle East, and Asia Pacific, with manufacturing and R&D centered in Switzerland. Founded in 1927 and headquartered in St. Gallen, Switzerland, it forms part of CSL Vifor following CSL Limited's acquisition of Vifor Pharma in 2023 for $11.7 billion, which expanded its pipeline to 37 products and strengthened capabilities in nephrology and iron therapies; recent developments include the European Commission's conversion of FILSPARI's conditional approval to standard marketing authorization in 2025, acquisition of Inositec AG in 2021 for INS-3001 in vascular calcification disorders, and a joint venture with Fresenius Medical Care (Vifor Fresenius Renal Pharma).